» Articles » PMID: 39519803

A Highly Sensitive UPLC-MS/MS Method for the Quantification of the Organic Cation Transporters' Mediated Metformin Uptake and Its Inhibition in Cells

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2024 Nov 9
PMID 39519803
Authors
Affiliations
Soon will be listed here.
Abstract

Metformin is the gold standard substrate for evaluating potential inhibitors of the organic cation transporters (OCTs). Here, we established a UPLC-MS/MS assay to quantify metformin in cell pellets with a range of 0.05-50 ng/mL using 6-deuterated metformin as an internal standard. We used an ion-pairing chromatographic approach with heptafluorobutyric acid, making use of a reverse-phase column, and overcame the associated ion-suppression via previously established post-column injection of aqueous ammonia. The assay was validated according to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommendations for bioanalytical methods. The established extraction procedure was simple, very fast and ensured almost 100% recovery of the analyte. The exceptionally sharp peak form and retention of the ion-pairing chromatography are superior to other methods and allow us to measure as sensitively as 0.05 ng/mL. We used the herein established and validated method to develop a cellular OCT inhibition assay by using metformin as a substrate and human embryonic kidney cells (HEK) overexpressing the OCTs 1-3. The method presented may be useful for identifying new OCT inhibitors, but also for drug-drug interactions and other pharmacokinetic studies, where accurate quantification of low metformin amounts in relevant tissues is mandatory.

Citing Articles

The "specific" P-glycoprotein inhibitor zosuquidar (LY335979) also weakly inhibits human organic cation transporters.

Bajraktari-Sylejmani G, Kamaraj R, Theile D, Pavek P, Weiss J Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39718614 DOI: 10.1007/s00210-024-03743-y.

References
1.
Solbach T, Grube M, Fromm M, Zolk O . Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization. J Cardiovasc Pharmacol. 2011; 58(4):409-17. DOI: 10.1097/FJC.0b013e3182270783. View

2.
Gergov M, Nenonen T, Ojanpera I, Ketola R . Compensation of matrix effects in a standard addition method for metformin in postmortem blood using liquid chromatography-electrospray-tandem mass spectrometry. J Anal Toxicol. 2015; 39(5):359-64. DOI: 10.1093/jat/bkv020. View

3.
Chandel N, Avizonis D, Reczek C, Weinberg S, Menz S, Neuhaus R . Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. Cell Metab. 2016; 23(4):569-70. DOI: 10.1016/j.cmet.2016.03.010. View

4.
Chaudhari K, Wang J, Xu Y, Winters A, Wang L, Dong X . Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm. PLoS One. 2020; 15(6):e0234571. PMC: 7289415. DOI: 10.1371/journal.pone.0234571. View

5.
Moussa B, Mahrouse M, Fawzy M . A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2018; 163:153-161. DOI: 10.1016/j.jpba.2018.09.052. View